Mirum Pharmaceuticals, Inc.
MIRM
$96.55
$3.914.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 11.97% | 4.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.97% | 4.09% | |||
| Cost of Revenue | 10.68% | 9.03% | |||
| Gross Profit | 12.28% | 2.98% | |||
| SG&A Expenses | 19.74% | -2.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.71% | -1.78% | |||
| Operating Income | -275.45% | 152.17% | |||
| Income Before Tax | -287.78% | 148.42% | |||
| Income Tax Expenses | 392.75% | -165.17% | |||
| Earnings from Continuing Operations | -297.25% | 149.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -297.25% | 149.56% | |||
| EBIT | -275.45% | 152.17% | |||
| EBITDA | -82.61% | 712.09% | |||
| EPS Basic | -298.78% | 148.69% | |||
| Normalized Basic EPS | -289.57% | 147.52% | |||
| EPS Diluted | -346.20% | 142.41% | |||
| Normalized Diluted EPS | -313.10% | 142.27% | |||
| Average Basic Shares Outstanding | -0.87% | 1.83% | |||
| Average Diluted Shares Outstanding | -11.92% | 14.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||